Comparative Pharmacology
Head-to-head clinical analysis: PEPCID versus PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID versus PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER.
PEPCID vs PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion by inhibiting cyclic AMP generation.
Competitive histamine H2-receptor antagonist; inhibits gastric acid secretion by blocking H2 receptors on parietal cells.
20 mg orally twice daily or 40 mg orally once daily at bedtime for duodenal ulcer; 40 mg orally once daily at bedtime for gastric ulcer; 20 mg orally once daily for GERD; 20 mg orally twice daily for erosive esophagitis; 20 mg intravenously every 12 hours for hospitalized patients with pathological hypersecretory conditions.
20 mg intravenously every 12 hours; or 40 mg intravenously once daily. For Zollinger-Ellison syndrome, initial dose 20 mg intravenously every 6 hours; adjust based on acid output.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours in normal renal function; prolonged to 8-10 hours in moderate renal impairment (CrCl 10-50 mL/min) and 15-20 hours in severe impairment (CrCl <10 mL/min); no significant change in hepatic impairment.
2.5–3.5 hours in normal renal function; prolonged to 6–8 hours in moderate renal impairment (CrCl <50 mL/min) and up to 20 hours in severe renal failure (CrCl <10 mL/min)
Renal: ~65-70% unchanged via tubular secretion (active) and glomerular filtration; hepatic metabolism (S-oxidation) ~30%; fecal: <5%.
Renal (65–70% unchanged via tubular secretion and glomerular filtration); biliary/fecal (minor, <10%)
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist